April 17 (Reuters) - The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
Pre-market 08:49:27 am | |||
737.2 USD | +0.50% | 780 | +5.81% |
02:14pm | US Stock Futures Flat Ahead of Big Earnings Reports, Key Inflation, Consumer Confidence, Manufacturing Numbers | MT |
02:14pm | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.47% | 664B | |
+28.29% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+14.02% | 234B | |
+4.89% | 199B | |
-10.06% | 196B | |
-4.04% | 148B | |
-10.94% | 145B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says